Volltext-Downloads (blau) und Frontdoor-Views (grau)

The present and future of project management in pharmaceutical R&D

  • Artificial intelligence (AI) technologies, such as machine learning or deep learning, have been predicted to highly impact future organizations and radically change the way how projects are managed. The Project Management Institute (PMI), the network of around 1.1 million certified project managers, ranked AI as one of the top three disruptors of their profession. In an own study on the effect of AI, 37% of the project management processes can be executed by machine learning and other AI technologies. In addition, Gartner recently postulated that 80% of the work of today's project managers may be eliminated by AI in 2030. This editorial aims to outline today's project and portfolio management in context of pharmaceutical research and development (R&D), followed by an AI-vision and a more tangible mission, and illustrate what the consequences of an AI-enabled project and portfolio management could be for pharmaceutical R&D.

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author of HS ReutlingenSchuhmacher, Alexander
DOI:https://doi.org/10.1016/j.drudis.2020.07.020
ISSN:1359-6446
eISSN:1878-5832
Publisher:Elsevier
Place of publication:Amsterdam
Document Type:Journal article
Language:English
Publication year:2021
Volume:26
Issue:1
Page Number:4
First Page:1
Last Page:4
DDC classes:610 Medizin, Gesundheit
Open access?:Nein
Licence (German):License Logo  In Copyright - Urheberrechtlich geschützt